Phase 1 Kidney Cancer Trial, Recruiting NCT06764771 Sponsor: Bristol-Myers Squibb Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT06764771
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older.
  • People who have been diagnosed with a locally advanced, inoperable, or metastatic solid tumour that has been confirmed by laboratory tissue testing, and whose tumour type fits the specific part of the trial they are being considered for (including kidney cancer, ovarian cancer, lung cancer, bowel cancer, pancreatic cancer, or tumours with a specific genetic change called KRAS G12C mutation).
  • People whose physical functioning is rated at a relatively high level, meaning they are fully active or have only minor restrictions on physical activity (confirmed by a standard medical assessment called ECOG Performance Status 0 or 1).
  • People whose cancer can be measured on scans according to a standard set of medical guidelines called RECIST v1.1.

Who may not be able to join:

  • People who have cancer that has spread to the brain or spinal cord area and has not yet been treated.
  • People who have cancer that has spread to the membranes surrounding the brain and spinal cord (sometimes called carcinomatous meningitis).
  • People who have reduced heart function or a significant heart condition.
  • People being considered for certain parts of the trial that involve a specific combination treatment: those with a history of lung inflammation (pneumonitis) or scarring of lung tissue (interstitial lung disease).
  • People being considered for those same combination treatment parts of the trial: those with a history of severe skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
  • Other criteria set out in the trial protocol may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Australian sites

Local Institution - 0031, Brisbane, Queensland

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
25 March 2025
Est. completion
15 October 2027

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants with Adverse Events (AEs); Number of participants with Serious AEs (SAEs); Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of deaths

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov